Sg Americas Securities, LLC Nektar Therapeutics Transaction History

Sg Americas Securities, LLC

  • $24.4 Billion
  • Q4 2024

A detailed history of Sg Americas Securities, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Sg Americas Securities, LLC holds 107,318 shares of NKTR stock, worth $94,439. This represents 0.0% of its overall portfolio holdings.

Number of Shares
107,318
Previous 95,637 12.21%
Holding current value
$94,439
Previous $124,000 19.35%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 17, 2025
BUY
$0.9 - $1.45 $10,512 - $16,937
11,681 Added 12.21%
107,318 $100,000
Q3 2024

Oct 03, 2024
BUY
$1.11 - $1.48 $24,736 - $32,981
22,285 Added 30.38%
95,637 $124,000
Q2 2024

Jul 12, 2024
BUY
$0.9 - $1.83 $25,504 - $51,858
28,338 Added 62.95%
73,352 $91,000
Q1 2024

May 06, 2024
SELL
$0.49 - $0.96 $27,769 - $54,406
-56,673 Reduced 55.73%
45,014 $42,000
Q4 2023

Jan 12, 2024
BUY
$0.42 - $0.57 $10,008 - $13,582
23,829 Added 30.61%
101,687 $57,000
Q3 2023

Oct 13, 2023
SELL
$0.51 - $1.05 $14,982 - $30,846
-29,378 Reduced 27.4%
77,858 $46,000
Q2 2023

Jul 10, 2023
SELL
$0.53 - $1.03 $36,958 - $71,824
-69,733 Reduced 39.4%
107,236 $62,000
Q1 2023

Apr 28, 2023
BUY
$0.64 - $3.15 $84,785 - $417,305
132,478 Added 297.76%
176,969 $124,000
Q4 2022

Feb 02, 2023
BUY
$2.03 - $4.28 $47,337 - $99,805
23,319 Added 110.14%
44,491 $101,000
Q3 2022

Oct 31, 2022
SELL
$3.04 - $5.14 $265,659 - $449,174
-87,388 Reduced 80.5%
21,172 $68,000
Q2 2022

Jul 29, 2022
BUY
$3.17 - $6.17 $103,728 - $201,894
32,722 Added 43.15%
108,560 $413,000
Q1 2022

Apr 29, 2022
BUY
$4.16 - $13.72 $315,486 - $1.04 Million
75,838 New
75,838 $409,000
Q4 2021

Feb 07, 2022
SELL
$10.83 - $18.41 $555,708 - $944,653
-51,312 Closed
0 $0
Q3 2021

Nov 01, 2021
SELL
$13.07 - $18.84 $302,413 - $435,919
-23,138 Reduced 31.08%
51,312 $922,000
Q2 2021

Aug 12, 2021
BUY
$16.52 - $20.4 $503,992 - $622,363
30,508 Added 69.43%
74,450 $1.28 Million
Q1 2021

May 13, 2021
SELL
$16.56 - $25.46 $987,389 - $1.52 Million
-59,625 Reduced 57.57%
43,942 $879,000
Q4 2020

Feb 04, 2021
BUY
$15.77 - $19.03 $1.29 Million - $1.56 Million
82,039 Added 381.08%
103,567 $1.76 Million
Q3 2020

Nov 09, 2020
SELL
$16.59 - $24.79 $396,534 - $592,530
-23,902 Reduced 52.61%
21,528 $357,000
Q2 2020

Jul 20, 2020
BUY
$16.86 - $23.44 $340,099 - $472,831
20,172 Added 79.86%
45,430 $1.05 Million
Q1 2020

Apr 30, 2020
SELL
$14.47 - $27.96 $305,056 - $589,452
-21,082 Reduced 45.49%
25,258 $451,000
Q4 2019

Jan 28, 2020
SELL
$15.87 - $23.12 $268,377 - $390,982
-16,911 Reduced 26.74%
46,340 $1 Million
Q3 2019

Nov 04, 2019
BUY
$16.91 - $36.27 $297,988 - $639,149
17,622 Added 38.62%
63,251 $1.15 Million
Q2 2019

Jul 29, 2019
SELL
$31.0 - $36.3 $3.1 Million - $3.62 Million
-99,859 Reduced 68.64%
45,629 $1.62 Million
Q1 2019

Apr 29, 2019
BUY
$31.58 - $46.35 $4.2 Million - $6.17 Million
133,045 Added 1069.24%
145,488 $4.89 Million
Q4 2018

Feb 01, 2019
SELL
$30.43 - $56.65 $1.04 Million - $1.93 Million
-34,022 Reduced 73.22%
12,443 $409,000
Q3 2018

Nov 06, 2018
BUY
$46.46 - $68.49 $133,851 - $197,319
2,881 Added 6.61%
46,465 $2.83 Million
Q2 2018

Aug 07, 2018
BUY
$46.25 - $104.45 $934,666 - $2.11 Million
20,209 Added 86.46%
43,584 $2.13 Million
Q1 2018

May 03, 2018
BUY
$57.4 - $108.44 $760,951 - $1.44 Million
13,257 Added 131.02%
23,375 $2.48 Million
Q4 2017

Jan 24, 2018
SELL
$23.02 - $60.5 $514,865 - $1.35 Million
-22,366 Reduced 68.85%
10,118 $604,000
Q3 2017

Nov 07, 2017
BUY
$17.79 - $24.0 $577,890 - $779,616
32,484
32,484 $780,000

Others Institutions Holding NKTR

# of Institutions
153
Shares Held
131M
Call Options Held
92.7K
Put Options Held
4.9K
View Full List

About NEKTAR THERAPEUTICS

NKTR Quotes by TradingView
  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $165M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email